Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience.
Mazzitelli M, Ciccullo A, Baldin G, Cauda R, Rusconi S, Giacomelli A, Oreni L, Borghi V, Mussini C, Guaraldi G, Sterrantino G, Lagi F, Candelaresi B, Cirioni O, De Vito A, Rossetti B, Torti C, Di Giambenedetto S. Mazzitelli M, et al. Among authors: cirioni o. Medicine (Baltimore). 2021 Oct 15;100(41):e27418. doi: 10.1097/MD.0000000000027418. Medicine (Baltimore). 2021. PMID: 34731116 Free PMC article.
Relationship between health-related quality of life measures and high HIV viral load in HIV-infected triple-class-experienced patients.
Bucciardini R, Pugliese K, Weimer L, Digregorio M, Fragola V, Mancini M, Maroccia Z, Ladisa N, Francisci D, Bellagamba R, Degli Antoni A, Guaraldi G, Cirioni O, Ortu F, Parruti G, Mannazzu M, Libertone R, Donnini S, Floridia M; ISS-NIA Study Group. Bucciardini R, et al. Among authors: cirioni o. HIV Clin Trials. 2014 Jul-Aug;15(4):176-83. doi: 10.1310/hct1504-176. HIV Clin Trials. 2014. PMID: 25143026
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.
Fabbiani M, Gagliardini R, Ciccarelli N, Quiros Roldan E, Latini A, d'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Del Pin B, Lombardi F, D'Avino A, Focà E, Colafigli M, Cauda R, Di Giambenedetto S, De Luca A; ATLAS-M Study Group. Fabbiani M, et al. J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123. J Antimicrob Chemother. 2018. PMID: 29668978 Clinical Trial.
Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center.
Brescini L, Della Martera F, Morroni G, Mazzanti S, Di Pietrantonio M, Mantini P, Candelaresi B, Pallotta F, Olivieri S, Iencinella V, Castelletti S, Cocci E, Polo RG, Veccia S, Cirioni O, Tavio M, Giacometti A. Brescini L, et al. Among authors: cirioni o. Antibiotics (Basel). 2021 Sep 19;10(9):1129. doi: 10.3390/antibiotics10091129. Antibiotics (Basel). 2021. PMID: 34572711 Free PMC article.
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection.
Weimer LE, Fragola V, Floridia M, Guaraldi G, Ladisa N, Francisci D, Bellagamba R, Degli Antoni A, Parruti G, Giacometti A, Manconi PE, Vivarelli A, D'Ettorre G, Mura MS, Cicalini S, Preziosi R, Sighinolfi L, Verucchi G, Libertone R, Tavio M, Sarmati L, Bucciardini R; ISS-NIA Study Group. Weimer LE, et al. J Antimicrob Chemother. 2013 Jan;68(1):193-9. doi: 10.1093/jac/dks341. Epub 2012 Sep 14. J Antimicrob Chemother. 2013. PMID: 22984206 Free PMC article.
Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study.
Di Pietrantonio M, Brescini L, Candi J, Gianluca M, Pallotta F, Mazzanti S, Mantini P, Candelaresi B, Olivieri S, Ginevri F, Cesaretti G, Castelletti S, Cocci E, Polo RG, Cerutti E, Simonetti O, Cirioni O, Tavio M, Giacometti A, Barchiesi F. Di Pietrantonio M, et al. Among authors: cirioni o. Antibiotics (Basel). 2022 Feb 28;11(3):321. doi: 10.3390/antibiotics11030321. Antibiotics (Basel). 2022. PMID: 35326784 Free PMC article.
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.
Bucciardini R, D'Ettorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer LE, Fragola V, Galluzzo CM, Pirillo MF, Lucattini S, Bellagamba R, Francisci D, Ladisa N, Degli Antoni A, Guaraldi G, Manconi PE, Vullo V, Preziosi R, Cirioni O, Verucchi G, Floridia M; ISS-NIA study group. Bucciardini R, et al. Among authors: cirioni o. Int J STD AIDS. 2012 Jul;23(7):459-63. doi: 10.1258/ijsa.2012.011391. Int J STD AIDS. 2012. PMID: 22843997 Clinical Trial.
No evidence of autoimmune disorders in antiretroviral-experienced HIV-1-infected individuals after long-term treatment with raltegravir.
Baroncelli S, Mezzaroma I, Fantauzzi A, Galluzzo CM, Antoni AD, Vullo V, Francisci D, Ladisa N, Vivarelli A, Cirioni O, Sighinolfi L, Weimer LE, Fragola V, Fidanza R, Cara A, Palmisano L. Baroncelli S, et al. Among authors: cirioni o. Antivir Ther. 2013;18(3):321-7. doi: 10.3851/IMP2433. Epub 2012 Oct 9. Antivir Ther. 2013. PMID: 23047152
223 results